Association studies have found that variation in the dopamine transporter gene (SLC6A3) is important in the susceptibility to attention-deficit hyperactivity disorder (ADHD) and response to methylphenidate treatment. An understanding of the biological mechanisms underlying these associations is still inconclusive. We assessed the relative activity of variable number tandem repeat (VNTR) alleles of SLC6A3 under basal and stimulated cellular conditions, as well as in the presence of pharmacological blockade of the dopamine transporter using gene-reporter constructs. The intron 8 VNTR 5-repeat allele is more active than the 6-repeat allele. In the presence of forskolin, both alleles were significantly induced. Blockade of the dopamine transporter did not influence activity of either allelic construct. No difference in activity between 9-and 10-repeat alleles of the 3 0 -untranslated region VNTR was observed under any experimental condition. These data suggest that the intron 8 VNTR is a functional variant with an ADHD susceptibility allele having reduced activity. The lack of enhanced allele-specific activity in response to treatment regimes suggests that differential activity under basal conditions is the primary mode of action.
Introduction
Attention-deficit hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder with global prevalence ranges between 3 and 6% of school-age children. Boys are more affected than girls with ratios of 4:1 in population studies and 9:1 in clinical studies. 1, 2 Persistent patterns of impulsiveness and inattention, with or without a component of hyperactivity, are typical characteristics. Dopaminergic abnormality, in particular a hypodopaminergic function, has long been hypothesized in ADHD. This is supported by pharmacological information and recent molecular genetic studies. Medications that inhibit the dopamine transporter (and thus increase dopamine availability in the synaptic cleft), such as methylphenidate and amphetamine, improve symptoms in ADHD and are the mainstay of treatment. Mice lacking the dopamine transporter show marked hyperactivity, believed to be caused by the depletion of dopamine because of the absence of reuptake. 3 The dopamine transporter mediates the active reuptake of dopamine from the synapse and is a principal regulator of dopaminergic neurotransmission. The gene was mapped to chromosome 5p15.3. It consists of 15 exons spanning B60 kb. 4 An initial examination of a 40-bp variable number tandem repeat (VNTR) polymorphism in the 3 0 untranslated region (UTR) of SLC6A3 reported a significant association with ADHD. 5 Follow-up studies reported inconsistent findings. However, meta-analyses of the published data indicate the importance of SLC6A3 as a susceptibility factor of minor effect for ADHD (odds ratio ¼ 1.17, 95% confidence interval ¼ 1.05-1.30). More recently, another SLC6A3 VNTR mapped to intron 8 was reported to associate with ADHD in English and Taiwanese samples. 6 In addition, a haplotype composed of the two VNTRs was found to confer susceptibility to ADHD. 6, 7 In addition to its potential contribution to ADHD risk, variation in SLC6A3 has been studied in relation to response to ADHD medication, primarily methylphenidate. As the primary action of methylphenidate is through blockade of the dopamine transporter, genetically mediated variation in expression and regulation of the transporter may contribute to drug response.
An initial report suggested a correlation between homozygosity for the 9-repeat allele (3 0 UTR VNTR) of SLC6A3 and good response to methylphenidate. 8 Similar results were found in a blind naturalistic study in medicationnaive Brazilian ADHD boys. 9 In contrast to the above findings, Kirley et al. 10 and Stein et al. 11 reported that ADHD individuals with one or two copies of the 10-repeat allele experienced a better response to methylphenidate. Lack of association of this VNTR with methylphenidate response has also been reported. 12 For other therapeutic compounds that block the transporter, for example, bupropion, similar effects of genotype on response have also been reported. 13 In vitro functional analysis of the SLC6A3 3 0 UTR VNTR variant has produced conflicting findings to date. Quantitative real-time PCR using RNA from the cerebellum, temporal lobe and lymphocytes found that increased levels of SLC6A3 expression correlated with 10-repeat alleles. 14 However, using reporter-gene assays, the same group 15 observed no differences in the activity of constructs containing the two alleles (9-and 10-repeat alleles) of SLC6A3. Another study, also using reporter constructs but transiently expressed in COS-7 cells, observed increased luciferase activity of constructs containing the 10-repeat compared with the 9-and 7-repeat alleles. 16 In the case of the intron 8 VNTR, two studies have addressed the functional impact of the common alleles. Using gene-reporter assays, the 5-repeat allele showed a small but significant increase in activity, under basal conditions, compared with the 6-repeat allele. 17 These authors also reported allele-specific induction in the presence of cocaine, forskolin and cellular depolarization. No significant difference in mRNA levels between 5-and 6-repeat carriers was observed in the postmortem human mid-brain samples, although a haplotype comprising the 10-repeat 3 0 UTR allele and the 6-repeat intron 8 allele showed a trend towards increased expression. 18 Regulation of SLC6A3 by both endogenous and exogenous means, especially by psychostimulants, is of considerable interest to both the understanding of phenotypes, for example, drug abuse/response, and in the development of novel treatment strategies.
In this study, we aimed to assess the functional status of intron 8 and 3
0 UTR VNTRs of SLC6A3 under basal conditions using the SH-SY5Y human neuroblastoma cell line. Furthermore, we aimed to investigate allele-specific activity under stimulated conditions. Cell stimulation was achieved by using potassium-invoked depolarization and/or by increasing cyclic adenosine monophosphate levels, a pathway through which dopamine receptors signal, by induction of adenylyl cyclase using forskolin. Both methods are likely to induce transcription factor expression/binding and simulate non-basal cellular conditions. SH-SY5Y cells express dopamine transporter mRNA and protein 19 and are vulnerable to MPP þ, 20 which is transported into the cell through the dopamine transporter. The expression of functional dopamine transporters allows for the investigation of potential pharmacogenetic interactions in the form of allelic-specific activity in response to a selective dopamine transporter inhibitor, GBR12935. UTR VNTR, 9-and 10-repeat alleles were amplified using the forward primer 5 0 TGTTCTAGATTGTGGTGTAGGGAAC GGC and the reverse primer 5 0 AGGTCTAGAAGAGTGTGG TCTGCAGGCT. Amplified sequences were TA-cloned into the pGEM-T vector (Promega, Southampton, UK). Intron 8 alleles were sub-cloned into the PstI site in the pRL-CMV vector (Promega), whereas 3 0 UTR VNTR alleles were subcloned into the XbaI site in the pGL3-Control vector (Promega). Sequence analysis using BigDye Terminator v3.1 Cycle Sequencing Kit (ABI PRISM, Applied Biosystems, Warrington, UK) was performed to confirm the fidelity and orientation of all inserts.
Materials and methods

Construction of the reporter vectors
Chemical reagents, cell culture and transfection 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (GBR12935) was purchased from Tocris Bioscience (Ellis Ville, MO, USA). Forskolin was purchased from Sigma-Aldrich (Arklow, Ireland).
SH-SY5Y cells were maintained in RPMI 1640 containing 10% fetal bovine serum at 37 1C and 5% CO 2 . Transfections were performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA).
For intron 8 constructs 100 ng of test constructs were cotransfected with 500 ng pGL3-Control vector. For 3 0 UTR Where appropriate, cells were serum-deprived for 1 h, followed by exposure to media containing vehicle (DMSO), 10 mM Forskolin or 100 nM GBR12935 for 24 h. Appropriate controls were generated using unmodified vectors exposed to identical treatment conditions. Experiments were conducted in triplicate for a minimum of three times. Depolarization was achieved by incubating cells with media containing 50 mM KCl for 5 min. 21 Each treatment regime was carried out on separate cell cultures.
Luciferase assay
Luciferase assays were performed using the dual-glow luciferase system (Promega) according to the manufacturer's instructions on a Victor plate reader (Perkin-Elmer, Waltham, MA, USA). Relative activities were first calculated by normalizing against the co-transfected reporter vector and then to the appropriately treated control vector, that is, containing no insert, to reduce potential non-specific affects of the treatment conditions on luciferase expression and activity.
Transcription factor binding site prediction The core-repeat sequence of the intron 8 VNTR was investigated for potential transcription factor binding sites using MatInspector (Genomatrix Software GmbH, Munich, Germany).
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Results
Gene-reporter constructs were created to assess the regulatory potential of polymorphic VNTRs within SLC6A3. DNA elements were cloned into restriction enzyme sites that attempted to appropriately mirror their genomic position (Figure 1 ). The intron 8 VNTR was cloned into the PstI site of the pRL-CMV vector (Figure 1a) , and the exon 15 3 0 UTR VNTR into the XbaI site of the pGL3-Control vector (Figure 1b) .
Reporter activities of two alleles of the intron 8 VNTR and exon 15 3 0 UTR VNTRs were determined under basal conditions. In addition, response to enhanced cyclic adenosine monophosphate signalling and blockade of the dopamine transporter in the presence or absence of cell depolarization was also investigated.
Intron 8 VNTR
Under basal conditions, the 5-repeat allele was B34% more active than the 6-repeat allele (Po0.05, t-test, Figure 2a) .
For non-depolarized cells, an exploratory two-way analysis of variance (ANOVA), testing allele, treatment and allele by treatment interaction, revealed highly significant effects for allele and treatment independently (P ¼ 0.0098 and P ¼ 0.0012, two-way ANOVA). No significant allele by treatment interaction was observed (P ¼ 0.7298, two-way ANOVA). In the presence of forskolin, both alleles showed increased activity compared with the vehicle-treated group (P ¼ 0.0191 for the 6-repeat allele and P ¼ 0.0139 for the 5-repeat allele, t-test, Figure 2b) .
For depolarized cells, the influence of the allele was significant (P ¼ 0.0108, two-way ANOVA). Treatment and genotype by treatment interaction were not significant (P ¼ 0.3688 and P ¼ 0.9549, two-way ANOVA, Figure 2c ).
Bioinformatic prediction of transcription factor binding sites using MatInspector identified potential binding sites for two transcription factor classes, 'human muscle-specific Mt binding site' and 'Vertebrate Sma and Mad related protein family of transcription factors'.
3
0 UTR VNTR Under basal conditions, no significant differences between the activities of the two alleles were observed (P ¼ 0.1595, t-test, Figure 3a) . Treatment, allele and allele by treatment interaction were not significant when cells were exposed to treatment regimes in the absence of depolarization (P ¼ 0.1889 for treatment, P ¼ 0.0843 for allele and P ¼ 0.6680 for allele by treatment interaction, two-way ANOVA, Figure 3b) .
In depolarized cells, no variable was significant (P ¼ 0.6434 for treatment, P ¼ 0.1651 for allele and P ¼ 0.9255 for treatment by allele, two-way ANOVA, Figure 3c ).
Discussion
We carried out functional analysis of two VNTRs mapped to intron 8 and the 3 0 UTR within SLC6A3 that are associated 
Functional analysis of two polymorphisms in SLC6A3
M Hill et al with ADHD. Appreciation of how susceptibility variants mediate gene expression and regulation is a step towards understanding the biology of disease susceptibility and drug response. Our data explore the activity of these alleles in the presence of cell stimuli and pharmacological blockade of the dopamine transporter. Cell stimulation was achieved using forskolin and potassium-induced depolarization. The depolarization regime used by Guindalini et al., 17 24 h exposure to 10 mM CaCl 2 and 40 mM KCl, proved toxic to the SH-SY5Y cells (data not shown), and thus we adopted a different protocol that has been shown to influence gene expression in the SH-SY5Y cell line up to 24 h after treatment. 21 
Intron 8 VNTR
In keeping with Guindalini et al., 17 we found the 5-repeat allele to be more active than the 6-repeat allele. Furthermore, the magnitude of the increase is very similar: 32% in the original study and 34% in our study. Therefore, the intron 8 VNTR is a functional variant when tested under basal conditions. However, in contrast to previous findings, we did not observe allele-specific activity in any treatment group, although forskolin did significantly activate both allelic constructs. These differences may be attributed to the use of different cell lines. We used the SH-SY5Y human neuroblastoma cell line, whereas the previous study used a mouse dopaminergic cell line (SN4741) derived from the substantia nigra. Differences in signalling mechanisms or membrane proteins, for example, receptors and transporters, may influence the ability of the treatment to regulate reporter activity. Furthermore, in this study, we used GBR12935 to test the effect of dopamine transporter blockade on allele activity as opposed to cocaine. Although both compounds function primarily through blockade of the dopamine transporter, the pharmacological activity of cocaine at other sites, for example, noradrenalin and serotonin transporters, could suggest that dopamine uptake blockade alone is not sufficient to produce differential activity of the two allelic constructs. Interestingly, depolarization abolished forskolin-induced activation of the constructs, suggesting that the additive effect of depolarization and forskolin observed using the SN4741 cell line might be cell context specific. The identification of two transcription binding sites within the VNTR needs to be confirmed experimentally, but could potentially be responsible for differential activity of the elements.
3
0 UTR VNTR Under basal conditions, activities of the two alleles tested are not significantly different when expressed as luciferase reporter constructs in the SH-SY5Y cell line. The nonsignificant increase in activity of the 9-repeat allele is consistent with previous results using similar constructs expressed in the SH-SY5Y cell line 15 and using SN4741 cells. 23 These data suggest that the 3 0 UTR VNTR per se is not a functional variant under these conditions. It is possible that reported associations with the 3 0 UTR VNTR are due to a functional variant in strong linkage disequilibrium. Future studies could investigate more complex constructs consisting of multiple regulatory elements that control the expression of SLC6A3.
It could be hypothesized that activating cell signalling pathways and manipulating dopamine transporter activity would result in modulation of reporter activity, possibly in an allele-specific manner. Such an interaction would potentially explain the mechanism underlying pharmacogenetic associations. However, these data do not support such a hypothesis as the 3 0 UTR VNTR does not seem to be regulated by the treatment conditions investigated in this study. It is possible that the underlying pharmacogenetic mechanisms were not directly tested in this study or that they are cell-specific.
These data contribute to the interpretation of reported phenotype associations. Specifically, associations of the reduced activity intron 8 allele with ADHD suggest that decreased SLC6A3 expression, and thus persistence of dopamine in the synapse, is a component of the aetiology of ADHD. This model is not consistent with the hypodopaminergic hypothesis. However, it is consistent with the SLC6A3 knockout mouse that has a hyperactivity phenotype that is paradoxically reversible with methylphenidate by modulating the dopamine/serotonin balance. 24 We conclude that the intron 8 VNTR is a functional variant with the 5-repeat allele more active than the 6-repeat allele. This repeat element is responsive to adenylate cyclase induction but not in an allele-specific manner. In contrast, the 3 0 UTR VNTR does not seem to be functional in this paradigm, and neither is it responsive to adenylate cyclase. The mechanism underlying the association in pharmacogenetic studies cannot be explained by direct allele-specific modulation of SLC6A3 expression. However, future pharmacogenetic studies should investigate the importance of the intron 8 functional variant with respect to drug response.
